4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Esperion Therapeutics, Inc. (ESPR) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Ann Arbor, United States with about 294 employees. Its market capitalization is roughly $819 million. In the fiscal year ended 2025-12-31, ESPR reported $403M in revenue and ($23M) in net income.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Interactive charts & full statements → Open the ESPR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $403M | $332M | $116M | $76M |
| Gross Profit | $274M | $264M | $73M | $48M |
| Operating Income (EBIT) | $60M | $54M | ($156M) | ($180M) |
| Net Income | ($23M) | ($52M) | ($209M) | ($234M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $80M | $168M | $87M | $82M | $65M | — |
| Gross Profit | $46M | $141M | $46M | $54M | $34M | — |
| Operating Income (EBIT) | ($7M) | $85M | ($10M) | $7M | ($22M) | — |
| Net Income | ($25M) | $62M | ($31M) | ($13M) | ($40M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | — | $0M | $0M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $466M | $344M | $206M | $248M | — |
| Total Liabilities | $768M | $732M | $661M | $572M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ESPR viewer.
About TickerBase · Data methodology & sources